Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isovue (iopamidol injection) is a nonionic, low-osmolar iodinated contrast agent developed and manufactured by Bracco Diagnostics. As a small molecule radiographic contrast medium, it is used to enhance the visualization of internal structures during diagnostic imaging procedures, including computed tomography (CT) and various forms of arteriography. The drug functions by increasing the attenuation of X-rays due to the presence of iodine atoms in the iopamidol molecule, thereby providing radiopaque contrast in blood vessels, organs, and tissues. It is FDA-approved for both intravenous and intra-arterial administration and has been extensively studied in specific patient populations, such as those with renal impairment undergoing imaging for conditions like liver disease or peripheral arterial disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isovue.